EMA committee recommends approval of guselkumab for moderate to severe plaque psoriasis Sep. 18, 2017
CHMP adopts negative opinion for masitinib marketing authorization in indolent systemic mastocytosis Sep. 18, 2017
Ontruzant becomes the first trastuzumab biosimilar to receive a positive opinion from CHMP Sep. 18, 2017
Santhera receives negative opinion from CHMP for its Type II extension application for Raxone in DMD Sep. 18, 2017
RSS